tranexamic acid
tranexamic acid: developed by 1 company · 7 clinical trials tracked · 1 FDA decision.
tranexamic acid evidence translation
What we can confirm
1 FDA record · 7 tracked trials
What it means
What to watch
Prepared research question
How could tranexamic acid → NEXS affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 2 study sponsors
Related indications
Development Pipeline (2)
| Company | Phase |
|---|---|
| NEXUS BIOPHARMA INC (NEXS) | Approved |
| NEXUS BIOPHARMA INC (NEXS) | Approved |
Clinical Trials (7)
Does Topical Use of Tranexamic Acid During a Cesarean Delivery Reduce Intra-surgical Bleeding? A Randomized ,Multi-center Trial
Primary endpoint: Uterine closure time (minutes)
Postoperative Continuous Intravenous Tranexamic Acid Infusion to Reduce Blood Loss in Non-Ambulatory Children With Cerebral Palsy Following Bilateral Bony Hip Reconstructive Surgery: A Phase III Parallel-Group Randomised Placebo-Controlled Trial
Primary endpoint: Mean change between treatment arms in postoperative haemoglobin mass loss, measured on postoperative day 5 or day of discharge (whichever is earlier) and estimated using the HAEmoglobin Mass loss DuRing the periOperative Period (HAEMDROP) formula
A Comparison Between the Efficacy of Tranexamic Acid and Adrenaline to Control Endobronchial Bleeding - A Randomized Controlled Trial
Primary endpoint: Immediate Hemostasis (Bleeding Cessation)
Topical Application of Tranexamic Acid (CYKLOKAPRON®) to Reduce Blood Loss During Spine Surgery
Primary endpoint: Maximal drop in systemic hemoglobin concentration during the postoperative period
Novel Strategies to Combat Post-Traumatic Osteoarthritis (PTOA):The Effects of Tranexamic Acid on Joint Inflammation and Cartilage Health in Anterior Cruciate Ligament Injured Patients
Primary endpoint: Synovial fluid IL-1
Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants
Primary endpoint: M/P ratio
A Double-blind, Randomised Controlled Trial Evaluating the Safety and Efficacy of Antifibrinolytics (Tranexamic Acid) in Patients With Haematological Malignancies With Severe Thrombocytopenia
Primary endpoint: The Proportion of Patients Who Die or Have Bleeding of WHO Grade 2 or Above by WHO Criteria During the First 30 Days From the First Dose of Trial Treatment, or Planned First Dose for Those Participants Who do Not Receive Treatment.
FDA Decisions1 records
Frequently asked questions
Who is developing tranexamic acid?
tranexamic acid is being developed by NEXUS BIOPHARMA INC.
How many clinical trials involve tranexamic acid?
BioSniper tracks 7 clinical trials involving tranexamic acid.
What is tranexamic acid's latest FDA decision?
The most recent tracked FDA decision for tranexamic acid is Approval for 1 INDICATIONS AND USAGE Tranexamic Acid in Sodium Chloride Injection is indicated in patients with hemophilia for short-term use (two to eight days) to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction. Tranexamic Acid in Sodium Chloride Injection is an antifibrinolytic indicated in patients with hemophilia for short-term use (two to eight days) to reduce or prevent hemorrhage and reduce the need for replacement therapy during and foll, dated April 16, 2024.